John Funkhouser
Family · Jackson, MSNPI 1821292046
Payments from drug & device makers
Across 292 payments — averaging $16.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$588
- Abbott$549
- Novo Nordisk$433
- AbbVie$415
- Lilly USA, LLC$397
- Amgen$338
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,700100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 37 | $588 |
| Abbott | 32 | $549 |
| Novo Nordisk | 28 | $433 |
| AbbVie | 30 | $415 |
| Lilly USA, LLC | 25 | $397 |
| Amgen | 21 | $338 |
| GSK | 22 | $300 |
| AstraZeneca | 16 | $268 |
| Sumitomo Pharma America, Inc. | 10 | $177 |
| Exact Sciences | 10 | $160 |
| Johnson & Johnson | 8 | $131 |
| Boehringer Ingelheim | 7 | $111 |
| Bayer | 6 | $98 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $92 |
| Corcept Therapeutics | 4 | $84 |
| Ironwood Pharmaceuticals, Inc | 4 | $72 |
| Amarin Pharma, Inc. | 3 | $65 |
| Sanofi Pasteur Inc. | 2 | $57 |
| Novartis | 2 | $38 |
| Currax Pharmaceuticals LLC | 2 | $31 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Astellas Pharma US Inc | 2 | $30 |
| Krystal Biotech Inc | 1 | $24 |
| Boston Scientific | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
| Corium, LLC | 1 | $19 |
| Genentech USA, Inc. | 2 | $18 |
| Merck | 1 | $16 |
| Medtronic | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
| Shield Therapeutics Inc | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$4,700 in reported general payments places this provider in the 90th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 243 | $219,689 |
| OzempicSemaglutide | 171 | $196,985 |
| JardianceEmpagliflozin | 119 | $123,351 |
| MounjaroTirzepatide | 88 | $97,191 |
| MyrbetriqMirabegron | 115 | $60,800 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 77 | $51,769 |
| XareltoRivaroxaban | 46 | $45,395 |
| FarxigaDapagliflozin Propanediol | 46 | $44,485 |
| EntrestoSacubitril/Valsartan | 31 | $27,165 |
| Repatha SureclickEvolocumab | 31 | $21,381 |
| LinzessLinaclotide | 22 | $17,451 |
| JanuviaSitagliptin Phosphate | 20 | $15,313 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $12,391 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $12,327 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $10,993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $588 | $219,689243 claims |
| Novo NordiskOzempic | $433 | $196,985171 claims |
| Boehringer IngelheimJardiance, Tradjenta | $111 | $130,935130 claims |
| Lilly USA, LLCMounjaro | $397 | $97,19188 claims |
| Astellas Pharma US IncMyrbetriq | $30 | $60,800115 claims |
| GSKTrelegy Ellipta | $300 | $51,76977 claims |
| Johnson & JohnsonXarelto | $131 | $45,39546 claims |
| AstraZenecaFarxiga | $268 | $44,48546 claims |
| MerckJanuvia, Janumet, Janumet Xr | $16 | $32,76643 claims |
| NovartisEntresto | $38 | $27,16531 claims |
| AbbVieLinzess, Synthroid | $415 | $21,46286 claims |
| Esperion Therapeutics, Inc.Nexlizet | $30 | $6,45011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,007 family providers in Mississippi.
Other family in Jackson
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Leondrea CollinsJackson$28K
- Elizabeth WilliamsJackson$18K
- Anna WalleyJackson$17K
- Teresa SpencerJackson$16K
- Catherine PageJackson$14K
- Mollie DotyJackson$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.